Skip to main content

Antithrombin

  • Protocol
  • First Online:
Haemostasis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 992))

Abstract

Antithrombin (AT) is a heparin cofactor and a member of the serine protease inhibitor family (serpin). The mature AT molecule is composed of 432 amino acids and it is produced mainly in the liver. Initially, several different AT activities in plasma were reported, leading to the classification of antithrombin in a range from I to IV. It was subsequently shown that these various antithrombin activities were the function of one molecule, antithrombin III, whose name was reduced to antithrombin at the meeting of the International Society in Thrombosis and Haemostasis in 1993. AT is an important protease inhibitor of thrombin and factor Xa. However, AT is also able to inhibit factors IXa, XIa, XIIab, kallikrein, and plasmin.

Given that AT is one of the major naturally occurring inhibitors of coagulation, acquired or hereditary deficiencies of this protein result in excessive thrombin generation. As a vast array of mutations are responsible for hereditary AT deficiencies, screening for their presence by DNA testing would require sequencing each entire gene involving numerous exons. Moreover, the knowledge of the gene mutation does not offer any benefit in the treatment of affected families, so the routine molecular characterization is not indicative. These defects are detected by functional or immunological assays. AT amidolytic assays are recommended for initial testing for AT deficiency. There is no need to routinely perform AT immunological assays. However, they are useful in order to distinguish type I from type II hereditary AT deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bock SC, Harris JF, Balazs I, Trent JM (1985) Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 39:67–69

    Article  PubMed  CAS  Google Scholar 

  2. Seegers WH, Johnson JF, Fell C (1954) An antithrombin reaction to prothrombin activation. Am J Physiol 176:97–103

    PubMed  CAS  Google Scholar 

  3. Rosenberg RD, Damus PS (1973) The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248:6490–6505

    PubMed  CAS  Google Scholar 

  4. Buchanan MR, Boneu B, Ofosu F, Hirsh J (1985) The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 65:198–201

    PubMed  CAS  Google Scholar 

  5. Kurachi K, Fujikawa K, Schmer G, Davie EW (1976) Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry 15:373–377

    Article  PubMed  CAS  Google Scholar 

  6. Scott CF, Colman RW (1989) Factors influencing the acceleration of human factor XIa inactivation by antithrombin III. Blood 73:1873–1879

    PubMed  CAS  Google Scholar 

  7. Stead N, Kaplan AP, Rosenberg RD (1976) Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 251:6481–6488

    PubMed  CAS  Google Scholar 

  8. Highsmith RF, Rosenberg RD (1974) The inhibition of human plasmin by human antithrombin-heparin cofactor. J Biol Chem 249:4335–4338

    PubMed  CAS  Google Scholar 

  9. Lane DA, Bayston T, Olds RJ et al (1997) Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 77:197–211

    PubMed  CAS  Google Scholar 

  10. Abildgaard U, Lie M, Odegard OR (1977) Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 11:549–553

    Article  PubMed  CAS  Google Scholar 

  11. Odegard OR, Lie M, Abildgaard U (1975) Heparin cofactor activity measured with an amidolytic method. Thromb Res 6:287–294

    Article  PubMed  CAS  Google Scholar 

  12. Kristensen SR, Rasmussen B, Pedersen S, Bathum L (2007) Detecting antithrombin deficiency may be a difficult task—more than one test is necessary. J Thromb Haemost 5:617–618

    Article  PubMed  CAS  Google Scholar 

  13. Jennings I, Kitchen S, Woods TA, Preston FE (2005) Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 31:66–72

    Article  PubMed  Google Scholar 

  14. Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blombäck N (2002) Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 99:2271–2272

    Article  PubMed  CAS  Google Scholar 

  15. Laurell C (1977) Electroimmunoassay. Scand J Clin Lab Invest 29:21–37

    Article  Google Scholar 

  16. Sas G, Pepper DS (1976) Detection of ­thrombin-antithrombin III complex by crossed immunoelectrophoresis. Thromb Res 9:95–97

    Article  PubMed  CAS  Google Scholar 

  17. Andrew M, Paes B, Milner R et al (1987) Development of the human coagulation ­system in the full-term infant. Blood 70: 165–172

    PubMed  CAS  Google Scholar 

  18. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L (1992) Maturation of the hemostatic system during childhood. Blood 80:1998–2005

    PubMed  CAS  Google Scholar 

  19. Monagle P, Barnes C, Ignjatovic V et al (2006) Developmental haemostasis—impact for clinical haemostasis laboratories. Thromb Haemost 95:362–372

    PubMed  CAS  Google Scholar 

  20. Demers C, Henderson P, Blajchman MA et al (1993) An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 69:231–235

    PubMed  CAS  Google Scholar 

  21. Refvem O, Fagerhol MK, Abildgaard U (1973) Changes in antithrombin III levels following cessation of anticoagulant therapy. Acta Med Scand 193:307–309

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Humana Press

About this protocol

Cite this protocol

Hepner, M., Karlaftis, V. (2013). Antithrombin. In: Monagle, P. (eds) Haemostasis. Methods in Molecular Biology, vol 992. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-339-8_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-339-8_28

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-338-1

  • Online ISBN: 978-1-62703-339-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics